RT Book, Section
A1 Fitzpatrick, Meghan E.
A1 Prendergast, Niall T.
A1 Rivera-Lebron, Belinda
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1186013018
T1 Pulmonary Venous Thromboembolism
T2 Current Medical Diagnosis & Treatment 2022
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264269389
LK accessmedicine.mhmedical.com/content.aspx?aid=1186013018
RD 2024/04/23
AB KEY  CLINICAL  UPDATES  IN  PULMONARY  VENOUS  THROMBOEMBOLISMDirect-acting  oral  anticoagulants  are  recommended  as  first-line  anticoagulation  for  most  patients.Discontinuation  of  anticoagulation  may  be  considered  after  3  months  for  patients–  With  major  transient/reversible  risk  factors  (such  as  fracture  of  lower  limb;  hip  or  knee  surgery)–  Who  were  hospitalized  because  of  heart  failure,  atrial  fibrillation,  or  myocardial  infarction.Guidelines  support  systemic  thrombolysis  for  high-risk  or  massive  PE  (hemodynamically  unstable)  with  low  risk  of  bleeding.Intermediate-risk  or  submassive  PE  patients  have  a  significant  decrease  in  incidence  of  hemodynamic  collapse  but  do  not  have  a  mortality  benefit  with  thrombolytic  therapy.They  do,  however,  have  an  increase  in  major  hemorrhagic  complications,  including  intracranial  hemorrhage.